Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AG 10

Drug Profile

AG 10

Alternative Names: AG10; BBP-265; Eidos Therapeutics AG10

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eidos Therapeutics
  • Class Fluorobenzenes; Heart failure therapies; Pyrazoles; Small molecules
  • Mechanism of Action Prealbumin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Transthyretin-related hereditary amyloidosis

Most Recent Events

  • 16 Nov 2019 Efficacy and adverse events data from a phase II extension trial for Transthyretin-related hereditary amyloidosis (Transthyretin amyloid cardiomyopathy) (ATTR) released by Eidos Therapeutics
  • 31 Oct 2019 Eidos Therapeutics plans pivotal phase III study in Amyloidosis and Amyloid polyneuropathy in the first quarter of 2020
  • 31 Oct 2019 Eidos Therapeutics initiates enrolment in a phase III ATTRibute-CM trial for Transthyretin amyloidosis cardiomyopathy in the US and Europe (NCT03860935)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top